Published in J Rheumatol on August 01, 1987
Urticarial vasculitis and syndromes in association with connective tissue diseases. Ann Rheum Dis (1991) 0.81
Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother (1984) 4.03
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) (1993) 2.88
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis (2010) 2.38
Morphoea in three siblings. J Eur Acad Dermatol Venereol (2001) 2.21
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
Complete Sequence and Enhancer Function of the Homologous DNA Regions of Autographa californica Nuclear Polyhedrosis Virus. J Virol (1986) 2.14
The association between porphyria cutanea tarda and diabetes mellitus: analysis of a long-term follow-up cohort. Br J Dermatol (2011) 2.09
Catastrophic antiphospholipid syndrome: clinical description and triggering factors in 8 patients. J Rheumatol (2000) 2.06
[Primary antiphospholipid syndrome: clinical and biological study of 36 cases]. Med Clin (Barc) (1994) 2.03
Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) (2001) 2.02
[50 years of LE cells: is it time for their retirement?]. Med Clin (Barc) (1998) 2.02
Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) (1998) 2.01
Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus (2008) 2.00
Hepatitis C virus infection mimicking primary Sjögren syndrome. A clinical and immunologic description of 35 cases. Medicine (Baltimore) (2001) 1.97
Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet (1990) 1.92
Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis (2010) 1.86
Dementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patients. Rheumatology (Oxford) (2004) 1.68
Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med (1994) 1.67
Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) (1999) 1.66
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
Systemic lupus erythematosus (SLE) in childhood: analysis of clinical and immunological findings in 34 patients and comparison with SLE characteristics in adults. Ann Rheum Dis (1998) 1.55
The clavicle hook plate for Neer type II lateral clavicle fractures. J Orthop Trauma (2009) 1.55
Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis (2004) 1.54
Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus (1997) 1.52
Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. Hum Reprod (1993) 1.51
[Primary Sjögren's syndrome and lymphatic proliferation]. Med Clin (Barc) (2000) 1.47
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother (1985) 1.46
Effect of salt intake on endothelium-derived factors in a group of patients with essential hypertension. Clin Sci (Lond) (2001) 1.44
Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. J Hepatol (1999) 1.44
Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis (2005) 1.44
[Relationship between cardiovascular risk profile and anti-hypertensive drug use. GEDEC (Spanish group of cardiovascular studies]. Med Clin (Barc) (2000) 1.42
A multiple-dose pharmacokinetic comparison of naproxen as a once-daily controlled-release tablet and a twice-daily conventional tablet. J Clin Pharmacol (1987) 1.40
[Functional abnormality of the diaphragm in the "shrinking lung" in systemic lupus erythematosus]. Rev Clin Esp (1993) 1.40
[Intolerance to hydroxychloroquine marketed in Spain (Dolquine) in patients with autoimmune conditions]. Rev Clin Esp (2004) 1.40
The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol (2005) 1.40
[Clinical course of idiopathic inflammatory myopathies: complications, survival and prognostic factors]. Med Clin (Barc) (1999) 1.39
Relative bioavailability of a new transdermal nitroglycerin delivery system. J Pharm Sci (1986) 1.39
[Primary Sjögren's syndrome: clinical and immunologic study of 80 patients]. Med Clin (Barc) (1997) 1.39
[Tuberculous meningitis with atypical presentation in a patient with human immunodeficiency virus infection]. Med Clin (Barc) (1992) 1.39
A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. Manag Care Interface (2001) 1.38
From genome to vaccine: in silico predictions, ex vivo verification. Vaccine (2001) 1.37
[Spanish contribution to the HOT (Hypertension Optimal Treatment) study. Final results. Spanish Investigators in the HOT study]. Med Clin (Barc) (1999) 1.37
A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes. J Immunol Methods (1995) 1.35
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
The lung in the antiphospholipid syndrome. Ann Rheum Dis (2002) 1.33
Metabolism of hexachlorobenzene in humans: association between serum levels and urinary metabolites in a highly exposed population. Environ Health Perspect (1997) 1.30
Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin Nephrol (1991) 1.25
Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) (2004) 1.25
A 40-kilodalton protein binds specifically to an upstream sequence element essential for muscle-specific transcription of the human myoglobin promoter. Mol Cell Biol (1992) 1.22
Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis (2003) 1.22
Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore) (1997) 1.22
Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum (1989) 1.21
Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension (2001) 1.21
Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension (2001) 1.19
Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res (1996) 1.17
Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) (2001) 1.17
Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol (1978) 1.16
Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis (2004) 1.15
Obstetrical outcome of pregnancy in patients with systemic Lupus erythematosus. A study of 60 cases. Eur J Obstet Gynecol Reprod Biol (1999) 1.15
Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients. Ann Rheum Dis (1990) 1.14
Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. J Immunol (2001) 1.13
Hepatoerythropoietic porphyria: a new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda? Lancet (1981) 1.12
Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis (1991) 1.12
Systemic lupus erythematosus evolving into systemic vasculitis: a report of five cases. Br J Rheumatol (1993) 1.11
Molecular mechanisms involved in macrophage survival, proliferation, activation or apoptosis. Immunobiology (2001) 1.10
Scaleup of immediate release oral solid dosage forms. Pharm Res (1993) 1.10
Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus (2003) 1.10
Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients. Medicine (Baltimore) (2001) 1.08
Characterization of the biochemical properties of recombinant ribonuclease III. Nucleic Acids Res (1990) 1.07
Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis (2004) 1.07
Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis (2006) 1.07
Renin-angiotensin system genetic polymorphisms and salt sensitivity in essential hypertension. Hypertension (2000) 1.07
Cardiovascular risk factors and the long-term outcome of lupus nephritis. QJM (2001) 1.06
Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis (1992) 1.06
Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients. Lupus (2006) 1.05